130 Initial evaluation from two pooled phase III studies suggest a positive trend toward slowing of cognitive decline in the mild AD subgroup. 131 A monoclonal antibody, mAb158 has high selectivity for soluble Aβ protofibrils, which are toxic to neurons.
← all excerpts
Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old.
1
—
—